Pharmacological treatment of social phobia

Psychiatry

Volumn 6, Issue 5, 2007, Pages 217-223

  Bhogal, Kuljit S ^a,b   Baldwin, David S ^a,b  

^a Department of Psychiatry ^*  (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

drug treatment; social anxiety disorder; social phobia

Indexed keywords

ALPRAZOLAM; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BROMAZEPAM; BUSPIRONE; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; OLANZAPINE; PAROXETINE; PETHIDINE; PHENELZINE; PINDOLOL; PLACEBO; PREGABALIN; SELEGELINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ADD ON THERAPY; AGITATION; ALCOHOL ABUSE; ANXIETY DISORDER; APPETITE DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; SWEATING; TACHYCARDIA; TREMOR; WEIGHT GAIN; XEROSTOMIA;

EID: 34247855859     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2007.02.007     Document Type: Review

References (62)

1. Bandelow B., and Stein D.J. Social anxiety disorder (2004), Marcel Dekker, New York
2. Lecrubier Y., and Weiller E. Comorbidities in social phobia. Int Clin Psychopharmacol 12 suppl 6 (1997) S17-S21
3. Stein D.J., Ono Y., Tajima O., and Muller J.E. The social anxiety disorder spectrum. J Clin Psychiatry 65 suppl 14 (2004) 27-33
4. Patel A., Knapp M., Henderson J., and Baldwin D. The economic consequences of social phobia. J Affect Disord 68 (2002) 221-233
5. Baldwin D., Anderson I.M., Nutt D., et al. Evidence-based guidelines for the treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19 (2005) 567-596
6. Schneier F.R., Johnson J., Hornig C.D., Liebowitz M.R., and Weissman M.M. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 49 (1992) 282-288
7. Schneier F.R., Blanco C., Antia S.X., and Liebowitz M.R. The social anxiety spectrum. Psychiatr Clin North Am 25 (2002) 757-774
8. Fahlen T. Core symptom pattern of social phobia. Depress Anxiety 4 (1996) 223-232
9. World Health Organization. The international classification of diseases and related health problems (ICD-10). 10th edn. (1992), WHO, Geneva
10. Blanco C., Raza M.S., Schneier F.R., and Liebowitz M.R. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 6 (2003) 427-442
11. Liebowitz M.R., Schneier F., Campeas R., et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 49 (1992) 290-300
12. Heimberg R.G. Cognitive-behavioral therapy for social anxiety disorder: current status and future directions. Biol Psychiatry 51 (2002) 101-108
13. Argyropoulos S., Hood S.D., Adrover M., et al. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biological Psychiatry 56 (2004) 503-509
14. Lane R., and Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review. J Clin Psychopharmacol 17 (1997) 208-221
15. Lader M., Stender K., Burger V., and Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19 (2004) 241-248
16. Allgulander C., Mangano R., Zhang J., et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19 (2004) 387-396
17. Liebowitz M.R., Gelenberg A.J., and Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62 (2005) 190-198
18. Stein D.J., Westenberg H.G., Yang H., Li D., and Barbato L.M. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6 (2003) 317-323
19. Stein M.B., Pollack M.H., Bystritsky A., Kelsey J.E., and Mangano R.M. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177 (2005) 280-288
20. Heimberg R.G., Liebowitz M.R., Hope D.A., et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 55 (1998) 1133-1141
21. Otto M.W., Pollack M.H., Gould R.A., Worthington III J.J., McArdle E.T., and Rosenbaum J.F. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 14 (2000) 345-358
22. Blomhoff S., Haug T.T., Hellstrom K., et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179 (2001) 23-30
23. Davidson J.R., Foa E.B., Huppert J.D., et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 61 (2004) 1005-1013
24. Liebowitz M.R., Heimberg R.G., Schneier F.R., et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long term outcome. Depress Anxiety 10 (1999) 89-98
25. Clark D.M., Ehlers A., McManus F., et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 71 (2003) 1058-1067
26. Haug T.T., Blomhoff S., Hellstrom K., et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 82 (2003) 312-318
27. Altamura A.C., Pioli R., Vitto M., and Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 14 (1999) 239-245
28. Van Ameringen M., Mancini C., and Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 39 (1996) 115-121
29. Stein M.B., Sareen J., Hami S., and Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158 (2001) 1725-1727
30. Liebowitz M.R., Mangano R.M., Bradwejn J., and Asnis G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66 (2005) 238-247
31. Rickels K., Mangano R., and Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24 (2004) 488-496
32. Davidson J.R., Potts N., Richichi E., et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13 (1993) 423-428
33. Versiani M., Nardi A.E., Figueira I., Mendlowicz M., and Marques C. Double-blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria 46 (1997) 167-171
34. Gelernter C.S., Uhde T.W., Cimbolic P., et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 8 (1991) 38-45
35. Pande A.C., Davidson J.R., Jefferson J.W., et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19 (1999) 341-348
36. Pande A.C., Feltner D.E., Jefferson J.W., et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24 (2004) 141-149
37. Turner S.M., Beidel D.C., and Jacob R.G. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 62 (1994) 350-358
38. van Vliet I.M., den Boer J.A., Westenberg H.G., and Ho Pian K.L. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 58 (1997) 164-168
39. Barnett S.D., Kramer M.L., Casat C.D., Connor K.M., and Davidson J.R. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 16 (2002) 365-368
40. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., and Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280 (1998) 708-713
41. Baldwin D., Bobes J., Stein D.J., Scharwachter I., and Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 175 (1999) 120-126
42. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 100 (1999) 193-198
43. Liebowitz M.R., Stein M.B., Tancer M., Carpenter D., Oakes R., and Pitts C.D. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63 (2002) 66-74
44. Wagner K.D., Berard R., Stein M.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61 (2004) 1153-1162
45. Lepola U., Bergtholdt B., St L.J., Davy K.L., and Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 65 (2004) 222-229
46. Katzelnick D.J., Kobak K.A., Greist J.H., Jefferson J.W., Mantle J.M., and Serlin R.C. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 152 (1995) 1368-1371
47. Van Ameringen M., Lane R.M., Walker J.R., et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158 (2001) 275-281
48. Liebowitz M.R., Demartinis N.A., Weihs K., et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64 (2003) 785-792
49. Versiani M., Nardi A.E., Mundim F.D., Alves A.B., Liebowitz M.R., and Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161 (1992) 353-360
50. Katschnig H., Stein M.B., and Buller R. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind placebo controlled clinical study. Eur Neuropsychopharmacol 2 (1997) 21-29
51. Noyes Jr. R., Moroz G., Davidson J.R., et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 17 (1997) 247-254
52. Schneier F.R., Goetz D., Campeas R., Fallon B., Marshall R., and Liebowitz M.R. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172 (1998) 70-77
53. Stein D.J., Cameron A., Amrein R., and Montgomery S.A. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 17 (2002) 161-170
54. van Vliet I.M., den Boer J.A., and Westenberg H.G. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2 (1992) 21-29
55. Fahlen T., Nilsson H.L., Borg K., Humble M., and Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 92 (1995) 351-358
56. Lott M., Greist J.H., Jefferson J.W., et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 17 (1997) 255-260
57. Kasper S., Stein D.J., Loft H., and Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186 (2005) 222-226
58. Kobak K.A., Greist J.H., Jefferson J.W., and Katzelnick D.J. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22 (2002) 257-262
59. van Vliet I.M., den Boer J.A., and Westenberg H.G. Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology 115 (1994) 128-134
60. Stein M.B., Fyer A.J., Davidson J.R., Pollack M.H., and Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156 (1999) 756-760
61. Davidson J., Yaryura-Tobias J., DuPont R., et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24 (2004) 118-125
62. Westenberg H.G., Stein D.J., Yang H., Li D., and Barbato L.M. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24 (2004) 49-55